Diseases targeted by Motility Incorporated

Motility Inc. is developing a small protein (LD22-4) for use as a therapeutic in the treatment of ocular diseases and hard-to-treat cancers.

Current research is focused on macular degeneration, proliferative vitreoretinopathy and malignant gliomas.

Motility Incorporated Developing Therapeutics for the Treatment of Eye Diseases